15:@0.490344:0.961646:0.507143:0.961646:0.507143:0.945381:0.490344:0.945381:0.008399:0.008399
百靈佳殷格翰:@0.449093:0.047478:0.549886:0.047478:0.549886:0.035100:0.449093:0.035100:0.016799:0.016799:0.016799:0.016799:0.016799:0.016799
!:@0.339549:0.209164:0.346898:0.209164:0.346898:0.198333:0.339549:0.198333:0.007350
!:@0.329451:0.394881:0.336800:0.394881:0.336800:0.384050:0.329451:0.384050:0.007350
!:@0.839214:0.410629:0.846564:0.410629:0.846564:0.399798:0.839214:0.399798:0.007350
在波士頓的創新合作:@0.070918:0.262376:0.282585:0.262376:0.282585:0.245047:0.070918:0.245047:0.023519:0.023519:0.023519:0.023519:0.023519:0.023519:0.023519:0.023519:0.023519
百靈佳殷格翰在美國波士頓的:@0.111964:0.288675:0.341270:0.288675:0.341270:0.275678:0.111964:0.275678:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
辦事處是以拓展旗下科學家和組織:@0.070919:0.308795:0.341181:0.308795:0.341181:0.295798:0.070919:0.295798:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
的網路為目標。百靈佳殷格翰目前:@0.070919:0.329213:0.341234:0.329213:0.341234:0.316216:0.070919:0.316216:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639
與哈佛大學幹細胞研究所的纖維化:@0.070919:0.349632:0.341181:0.349632:0.341181:0.336635:0.070919:0.336635:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
網路合作，研究治療纖維化疾病的:@0.070919:0.370050:0.341234:0.370050:0.341234:0.357053:0.070919:0.357053:0.018080:0.018080:0.018080:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639
新療法。:@0.070919:0.390468:0.141474:0.390468:0.141474:0.377471:0.070919:0.377471:0.017639:0.017639:0.017639:0.017639
纖維化的特徵是器官纖維:@0.131402:0.410887:0.341305:0.410887:0.341305:0.397890:0.131402:0.397890:0.019226:0.019226:0.019226:0.019226:0.019226:0.019226:0.019226:0.019226:0.019226:0.019226:0.017639
結締組織的病理增生。百靈佳殷格:@0.070919:0.431305:0.341234:0.431305:0.341234:0.418308:0.070919:0.418308:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639
翰與哈佛大學科學家針對特發性肺:@0.070919:0.451724:0.341181:0.451724:0.341181:0.438727:0.070919:0.438727:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
纖維化、慢性腎臟衰竭和非酒精性:@0.070919:0.472142:0.341234:0.472142:0.341234:0.459145:0.070919:0.459145:0.018080:0.018080:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639
脂肪性肝炎之類的疾病展開研究。:@0.070919:0.492560:0.341234:0.492560:0.341234:0.479563:0.070919:0.479563:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.017639
他們尋找纖維化根本的病理生理機:@0.070919:0.512979:0.341181:0.512979:0.341181:0.499982:0.070919:0.499982:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
轉，或可成為治療纖維化疾病的轉:@0.070919:0.533397:0.341234:0.533397:0.341234:0.520400:0.070919:0.520400:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639
折點。這個合作的好處是研究員現:@0.070919:0.553816:0.341234:0.553816:0.341234:0.540819:0.070919:0.540819:0.018080:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639
在得以比以前更深入的開展研究工:@0.070919:0.574234:0.341181:0.574234:0.341181:0.561237:0.070919:0.561237:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
作，利用協同效應，有效分享資源。:@0.070919:0.594653:0.345679:0.594653:0.345679:0.581655:0.070919:0.581655:0.017639:0.013908:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.013908:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
跨越國界:@0.364569:0.114891:0.458643:0.114891:0.458643:0.097561:0.364569:0.097561:0.023519:0.023519:0.023519:0.023519
2015 年百靈佳殷格翰結合公司:@0.401527:0.141190:0.634411:0.141190:0.634411:0.128193:0.401527:0.128193:0.008819:0.008819:0.008819:0.008819:0.003579:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
本身優勢，發揮協同作用的效果，:@0.364573:0.161920:0.634448:0.161920:0.634448:0.148923:0.364573:0.148923:0.018080:0.018080:0.018080:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.017639
及大膽投入外部創新，為其全球研:@0.364573:0.182339:0.634430:0.182339:0.634430:0.169342:0.364573:0.169342:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
究組織推出一個新策略。「無國界:@0.364573:0.202757:0.634448:0.202757:0.634448:0.189760:0.364573:0.189760:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.017639:0.018080:0.018080:0.018080:0.017639
研究」行動代表的是一個新方法，:@0.364573:0.223176:0.634430:0.223176:0.634430:0.210178:0.364573:0.210178:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.017639
在百靈佳殷格翰內外的核心治療領:@0.364573:0.243594:0.634342:0.243594:0.634342:0.230597:0.364573:0.230597:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
域探討科學新方法和創新的技術，:@0.364573:0.264012:0.634430:0.264012:0.634430:0.251015:0.364573:0.251015:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.017639
或可成為公司未來的重點領域。:@0.364573:0.284431:0.611517:0.284431:0.611517:0.271434:0.364573:0.271434:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
    生命科學研究的重要性在亞洲:@0.364573:0.304849:0.634414:0.304849:0.634414:0.291852:0.364573:0.291852:0.010134:0.010134:0.010135:0.010134:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
快速提升，為某些重點領域的藥:@0.364573:0.325268:0.634377:0.325268:0.634377:0.312270:0.364573:0.312270:0.019544:0.019544:0.019544:0.017639:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.017639
學研發帶來重大的新契機。再生醫:@0.364573:0.345686:0.634430:0.345686:0.634430:0.332689:0.364573:0.332689:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.017639
學正是這些具有優勢的領域之一。:@0.364573:0.366104:0.634430:0.366104:0.634430:0.353107:0.364573:0.353107:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.017639
與日本京都大學簽訂的三年合作目:@0.364573:0.386523:0.634342:0.386523:0.634342:0.373526:0.364573:0.373526:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
前已在著手進行。百靈佳殷格翰與:@0.364573:0.406941:0.634430:0.406941:0.634430:0.393944:0.364573:0.393944:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
京都大學的科學家合作研究新的療:@0.364573:0.427360:0.634342:0.427360:0.634342:0.414363:0.364573:0.414363:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
法，以恢復聽力受損者的聽力。有:@0.364573:0.447778:0.634448:0.447778:0.634448:0.434781:0.364573:0.434781:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.018080:0.017639
這種嚴重問題的人數超過三億六千:@0.364573:0.468196:0.634342:0.468196:0.634342:0.455199:0.364573:0.455199:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
萬人，其中三千兩百萬人是兒童。:@0.364573:0.488615:0.634450:0.488615:0.634450:0.475618:0.364573:0.475618:0.018080:0.017641:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.017639
由於全球人口老化，而聽力缺損又:@0.364573:0.509033:0.634430:0.509033:0.634430:0.496036:0.364573:0.496036:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
會隨著年齡俱增，所以預期這種情:@0.364573:0.529452:0.634430:0.529452:0.634430:0.516455:0.364573:0.516455:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
況的患病率會大幅增加。目前並沒:@0.364573:0.549870:0.634430:0.549870:0.634430:0.536873:0.364573:0.536873:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.017639
有可恢復聽力缺損的有效療法，患:@0.364573:0.570288:0.634430:0.570288:0.634430:0.557291:0.364573:0.557291:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.017639
者必須依賴助聽器。:@0.364573:0.590707:0.523323:0.590707:0.523323:0.577710:0.364573:0.577710:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
    聯合研究小組在構思一個新的:@0.364573:0.611125:0.634414:0.611125:0.634414:0.598128:0.364573:0.598128:0.010134:0.010134:0.010135:0.010134:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
概念，希望瞭解內耳受損的毛細:@0.364573:0.631544:0.634377:0.631544:0.634377:0.618547:0.364573:0.618547:0.019544:0.017639:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.019544:0.017639
胞再生的機轉。對聽力受損的人來:@0.364573:0.651962:0.634430:0.651962:0.634430:0.638965:0.364573:0.638965:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
說，這些感官細胞已無法正常發揮:@0.364573:0.672380:0.634430:0.672380:0.634430:0.659383:0.364573:0.659383:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
功能，而新療法的目的就是在於恢:@0.364573:0.692799:0.634430:0.692799:0.634430:0.679802:0.364573:0.679802:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
復它們的正常功能，克服助聽器的:@0.364573:0.713217:0.634430:0.713217:0.634430:0.700220:0.364573:0.700220:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
限制。:@0.364573:0.733636:0.417490:0.733636:0.417490:0.720639:0.364573:0.720639:0.017639:0.017639:0.017639
        百靈佳殷格翰於 2016 年 9 月:@0.364573:0.754054:0.634388:0.754054:0.634388:0.741057:0.364573:0.741057:0.008819:0.002910:0.008819:0.002910:0.008819:0.002910:0.008819:0.003216:0.017939:0.017939:0.017939:0.017939:0.017939:0.017939:0.017639:0.004487:0.008819:0.008819:0.008819:0.008819:0.004485:0.017639:0.004486:0.008819:0.004485:0.017639
在京都大學醫學創新中心設立辦事:@0.364573:0.774473:0.634342:0.774473:0.634342:0.761475:0.364573:0.761475:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
處，以建立與日本科學家的其他合:@0.364573:0.794891:0.634430:0.794891:0.634430:0.781894:0.364573:0.781894:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
作。:@0.364573:0.815309:0.399851:0.815309:0.399851:0.802312:0.364573:0.802312:0.017639:0.017639
    為拓展百靈佳殷格翰在聽力缺:@0.364573:0.835728:0.634414:0.835728:0.634414:0.822731:0.364573:0.822731:0.010134:0.010134:0.010135:0.010134:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
損領域的研究，「無國界研究」小:@0.364573:0.856146:0.634448:0.856146:0.634448:0.843149:0.364573:0.843149:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639
組最近展開與南京的中國東南大學:@0.364573:0.876565:0.634342:0.876565:0.634342:0.863567:0.364573:0.863567:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
另一項合作，將著重於以相輔相成:@0.364573:0.896983:0.634430:0.896983:0.634430:0.883986:0.364573:0.883986:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
的方法恢復聽力。:@0.364573:0.917401:0.505684:0.917401:0.505684:0.904404:0.364573:0.904404:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
合作抗癌:@0.658730:0.402683:0.752804:0.402683:0.752804:0.385354:0.658730:0.385354:0.023519:0.023519:0.023519:0.023519
 百靈佳殷格翰癌症研究的目標:@0.689481:0.428982:0.928571:0.428982:0.928571:0.415985:0.689481:0.415985:0.009784:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
是研發新療法改善患者的生活。為:@0.658736:0.449102:0.928593:0.449102:0.928593:0.436105:0.658736:0.436105:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.017639
達到此一目標，本公司持續拓展與:@0.658736:0.469520:0.928593:0.469520:0.928593:0.456523:0.658736:0.456523:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
學術機構、生物科技公司的合作網:@0.658736:0.489939:0.928593:0.489939:0.928593:0.476942:0.658736:0.476942:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
路。這些合作著重於新興科技，希:@0.658736:0.510357:0.928611:0.510357:0.928611:0.497360:0.658736:0.497360:0.017639:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.018080:0.017639:0.018080:0.017639
望在治療方面能獲得真正的突破，:@0.658736:0.530775:0.928593:0.530775:0.928593:0.517778:0.658736:0.517778:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.017639
而患者與照顧者還有醫療系統的需:@0.658736:0.551194:0.928505:0.551194:0.928505:0.538197:0.658736:0.538197:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
求則為研究人員指引方向。:@0.658736:0.571612:0.870403:0.571612:0.870403:0.558615:0.658736:0.558615:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
      其中一項就是與位於奧地:@0.658736:0.592031:0.928512:0.592031:0.928512:0.579034:0.658736:0.579034:0.008819:0.002910:0.008819:0.002910:0.008819:0.006604:0.021325:0.021325:0.021325:0.021325:0.021325:0.021325:0.021325:0.021325:0.021325:0.021325:0.017639
利 因 斯 布 魯 克 的 生 物科 技 公 司:@0.658736:0.612449:0.928585:0.612449:0.928585:0.599452:0.658736:0.599452:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.021026:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639
ViaTherapeutics 研究癌症療法的:@0.658736:0.632868:0.928578:0.632868:0.928578:0.619870:0.658736:0.619870:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.004796:0.019186:0.019186:0.019186:0.019186:0.019186:0.019186:0.017639
策略性合作。二○一五年四月，:@0.658736:0.653286:0.928576:0.653286:0.928576:0.640289:0.658736:0.640289:0.019720:0.019720:0.019720:0.019720:0.017639:0.019720:0.019720:0.019720:0.019720:0.019720:0.019720:0.019720:0.017639:0.017639
百 靈 佳 殷 格 翰 的 創 業基 金 成 為:@0.658736:0.673704:0.928585:0.673704:0.928585:0.660707:0.658736:0.660707:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.021026:0.017639:0.003378:0.017639:0.003378:0.017639:0.003378:0.017639
ViaTherapeutics 的主要投資人，:@0.658736:0.694123:0.928578:0.694123:0.928578:0.681126:0.658736:0.681126:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.008819:0.004870:0.019480:0.019480:0.019480:0.019480:0.019480:0.017639:0.017639
因為溶解病毒成為癌症研究最具希:@0.658736:0.714541:0.928505:0.714541:0.928505:0.701544:0.658736:0.701544:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
望的新興療法之一。自 2016 年 9:@0.658736:0.734960:0.928609:0.734960:0.928609:0.721962:0.658736:0.721962:0.019756:0.019756:0.019756:0.019756:0.019756:0.019756:0.019756:0.017639:0.019756:0.017639:0.004939:0.008819:0.008819:0.008819:0.008819:0.004937:0.017639:0.004939:0.008819
月以來這兩家公司便攜手對破壞癌:@0.658736:0.755378:0.928505:0.755378:0.928505:0.742381:0.658736:0.742381:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
細胞的溶解病毒展開初期研究。:@0.658736:0.775796:0.905681:0.775796:0.905681:0.762799:0.658736:0.762799:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
溶解病毒是以感染與破壞:@0.719220:0.796215:0.928593:0.796215:0.928593:0.783218:0.719220:0.783218:0.019173:0.019173:0.019173:0.019173:0.019173:0.019173:0.019173:0.019173:0.019173:0.019173:0.017639
癌細胞的方式發揮作用。這個過程:@0.658736:0.816633:0.928593:0.816633:0.928593:0.803636:0.658736:0.803636:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.017639
也會導致腫瘤抗原的釋放，腫瘤抗:@0.658736:0.837052:0.928593:0.837052:0.928593:0.824054:0.658736:0.824054:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.017639
原一般是隱藏在身體細胞內，沒有:@0.658736:0.857470:0.928593:0.857470:0.928593:0.844473:0.658736:0.844473:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.017639
被免疫系統發現，而所謂的原位接:@0.658736:0.877888:0.928593:0.877888:0.928593:0.864891:0.658736:0.864891:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.018045:0.017639
種疫苗效應就會引起適應性免疫系:@0.658736:0.898307:0.928505:0.898307:0.928505:0.885310:0.658736:0.885310:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.018009:0.017639
統對抗腫瘤細胞的持續性反應。:@0.658736:0.918725:0.905681:0.918725:0.905681:0.905728:0.658736:0.905728:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639:0.017639
內耳的毛細胞:@0.071429:0.660998:0.182301:0.660998:0.182301:0.647382:0.071429:0.647382:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
溶解病毒是癌症研究最有希望的:@0.667740:0.125917:0.928606:0.125917:0.928606:0.112301:0.667740:0.112301:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
新興療法之一。:@0.667740:0.146954:0.797092:0.146954:0.797092:0.133338:0.667740:0.133338:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479